| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Department of Urology, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden and 2 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
Requests for reprints: Jan-Erik Damber, Department of Urology, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden. Phone: 46-31-342-3977; Fax: 46-31-416347; E-mail: jan-erik.damber{at}urology.gu.se.
Purpose: Chronic inflammation is linked to the development of cancer in several organs, including the prostate. Up-regulated cyclooxygenase-2 (COX-2) may play a role in influencing cell proliferation, differentiation, apoptosis, or angiogenesis. This study aimed to derive data from human prostate cancer to investigate whether chronic inflammation and angiogenesis were correlated with the expression of COX-2.
Experimental Design: In this study, we did double-immunohistochemical analysis of a set of 43 human prostate cancer for COX-2 expression and the correlation with T-lymphocyte and macrophage densities and CD31-marked microvessel density (MVD) in situ.
Results: COX-2 positive staining was detected in 40/43 cancer samples with the very heterogeneous expression. Elevated COX-2 expression was associated with high Gleason score (P = 0.002). Foci of chronic inflammation were found in all 43 samples. COX-2positive areas were noted with high T-lymphocyte and macrophage densities than COX-2negative tumor areas (P < 0.0001 and P = 0.001, respectively). MVD were also found higher in COX-2positive areas than in COX-2negative tumor areas (P = 0.001).
Conclusions: This study shows a novel relationship between COX-2 expression and the local chronic inflammation within prostate cancer and the increased angiogenesis. It is likely that the proinflmmatory cytokines, released by T-lymphocytes and macrophages, up-regulate COX-2 in adjacent tumor cells and stimulate the angiogenesis in stromal tissues. These findings suggest that COX-2 may be an effective therapeutic target in prostate cancer treatment.
Key Words: COX-2 prostate cancer inflammation
This article has been cited by other articles:
![]() |
M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies Endocr. Rev., April 1, 2008; 29(2): 234 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mehar, P. Macanas-Pirard, A. Mizokami, Y. Takahashi, G. E. N. Kass, and H. M. Coley The Effects of Cyclooxygenase-2 Expression in Prostate Cancer Cells: Modulation of Response to Cytotoxic Agents J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1181 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nie, Y. Guo, D. Yang, Y. Tang, Y. Chen, M.-T. Wang, A. Zacharek, Y. Qiao, M. Che, and K. V. Honn Thromboxane A2 Receptors in Prostate Carcinoma: Expression and Its Role in Regulating Cell Motility via Small GTPase Rho Cancer Res., January 1, 2008; 68(1): 115 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, J. K.L. Colby, P. Yang, S. M. Fischer, R. A. Newman, and R. D. Klein The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue Carcinogenesis, January 1, 2008; 29(1): 120 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Mitchell, R. Lucas, I. Vojnovic, K. Hasan, J. R. Pepper, and T. D. Warner Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events FASEB J, December 1, 2006; 20(14): 2468 - 2475. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kobayashi, R. J. Barnard, S. M. Henning, D. Elashoff, S. T. Reddy, P. Cohen, P. Leung, J. Hong-Gonzalez, S. J. Freedland, J. Said, et al. Effect of Altering Dietary {omega}-6/{omega}-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2 Clin. Cancer Res., August 1, 2006; 12(15): 4662 - 4670. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, W. Ouyang, and C. Huang Inflammation, a Key Event in Cancer Development Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |